Long-acting sinus-to-brain and oral extended-release drug-delivery platforms providing weeks-to-months of controlled drug release. 45+ day sinus-placed sustained-release formulation for chronic rhinosinusitis and direct-to-brain delivery via the olfactory pathway, plus oral extended-release therapies for obesity, metabolic and neurological disorders to improve efficacy and adherence.